Biotech Values

[jq1234]

if it does turn out that mylan starts trials

By trial, if you mean safety and efficacy trial required by FDA, it means FDA deemed Mylan's application CANNOT be processed via 505j ANDA. I believe Mylan will disclose it - MNTA will too. This is material information since both are in court challenging Teva Copaxone patent. Without disclosure, it would mislead investors that the application is still via 505j. On the other hand, if you mean bioequivalence trial, there isn't any consequence.